The intracellular stemness marker ALDH is another potential target for novel cancer therapies; different inhibitors of multi-isoform ALDH (specifically ALDH1A1, ALDHA2, ALDH3A1) have been developed and their biological activity has been evaluated in different types of tumor cells, including melanoma cells [132]. This evidence concerns the gene LDHA and melanoma.